Low-field strength MRI can successfully visualize common lung problems.
In the next step toward increasing MRI use with lung imaging, new research shows 0.55T MRI has the potential to effectively reveal common lung abnormalities.
While CT is largely employed for lung imaging, MRI is an attractive alternative because it is free of ionizing radiation. Ongoing efforts have explored the use of 1.5T and 3.0T MRI, but this is the first investigation to assess whether 0.55T can be useful clinically.
In a study published June 10 in Radiology: Cardiothoracic Imaging, a team of researchers from National Institutes of Health shared data that shows capturing lung images with a 0.55T MRI with a closed-bore super-conducting magnet design performs comparably to conventional CT.
Related Content: 0.55T MRI Performs Comparably to CT with COVID-19 Imaging
“Our findings in this small sample of patients indicate excellent image quality that shows promise for clinical diagnosis and evaluation of common lung diseases,” said the team led by Adrienne E. Campbell-Washburn, Ph.D., the staff scientist who leads the National Heart, Lung, and Blood Institute’s Laboratory of MRI Technology.
For their study, they captured respiratory-triggered T2-weighted turbo-spin echo MRI image sets on 18 participants with common lung abnormalities between November 2018 and December 2019. The average participant age was 59 years, and the average acquisition time was 10.5 minutes.
Axial multi-section imaging yielded full lung coverage using (A) CT (reformatted to 0.8 × 0.8 × 6 mm) and (B) T2-weighted MRI (1.1 × 1.1 × 6 mm) in a 69-year-old woman with bronchiectasis, cavitary lesions, and scattered pulmonary nodules.
Credit: RSNA
The MRI images were captured with a clinical 1.5T MRI that had been modified to operate at 0.55T. Lung imaging was performed with an 18-channel spine phased-array coil and a six-channel body phased-array coil for 0.55T.
Axial multi-section imaging yielded full lung coverage using (A) CT (reformatted to 0.8 × 0.8 × 6 mm) and (B) T2-weighted MRI (1.1 × 1.1 × 6 mm) in a 41-year-old woman with lymphangioleiomyomatosis resulting in innumerable thin-walled pulmonary cysts.
Credit: RSNA
Three radiologists assessed the exams, compared them to the same images captured with conventional CT, and graded them on a five-point scale with “1” indicating the images were non-diagnostic in quality and “5” indicating excellent image quality.
According to their evaluation, most of the images were deemed “good,” with 37 out of 54 images receiving a score of 4 or 5. Overall, the team said, there was almost perfect consensus between MRI and CT for consolidations, cavitation, mucus plug, scattered nodules, bronchiectasis or bronchial wall thickening, and pleural effusion (k range, 0.61 to 1). However, there was less agreement between the modalities for ground-glass opacities, tree-in-bud pattern nodularity, and scarring (k range, 0.48 to 0.57).
The next step, the team said, is an effort to focus on eliminating motion artifacts that cause image-quality disruptions.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.